And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is, not surprisingly, rather modest. We plan to putter around the castle, tend to the grounds, promenade with the mascot, and catch up on our napping. And what about you? This may be a good time to bolster the economy by placing a curbside pickup order from a local eatery. You could enjoy the weather and take a constitutional. Or reach out to someone feeling isolated. Well, whatever you do, have a grand time. But, remember, wear a mask. Enjoy, and see you soon. …

The European Commission is in advanced talks with Johnson & Johnson (JNJ) to reserve or buy up-front doses of its Covid-19 vaccine under development, Reuters reports. The move would be the first arranged by the European Union executive since it was mandated by the 27 EU national governments to use an emergency fund of more than $2.3 billion to strike deals with up to six vaccine makers. It was unclear whether any deal would involve an advance purchase of the vaccine in testing, or an option to buy it.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy